Strong Performance in the First Half of the Year
Novonesis has reported an impressive 9% organic sales growth in the first half of the year, highlighting its robust position in the biosolutions sector. This growth reflects the increasing demand for their innovative products and solutions, establishing Novonesis as a leader in the market.
CEO’s Insight on Company Performance
Ester Baiget, the President and CEO of Novonesis, expressed her satisfaction with the company's performance during the first half of the year. She noted that the strong sales growth is an indication of the effective strategies implemented to enhance customer satisfaction and product delivery. Baiget stated, "Demand for our biosolutions remains strong, prompting us to raise the lower limit of our full-year sales guidance to 6-8%." This upward revision is crucial for aligning with the company’s ambitious growth targets.
Key Highlights of H1 Results
In the recent financial report, several key points stood out:
- Organic sales growth was recorded at 9%, with notable contributions from specific sectors: Food & Health rose by 10%, while Planetary Health achieved a growth rate of 9%.
- Emerging markets continued to show strength, achieving 12% growth, whereas developed markets followed closely with 8%.
- The company's cost synergies reached a full run rate of 100%, indicating efficiency in operations.
- Adjusted EBITDA margin improved to 37.4%, reflecting the company's strategic focus on profitability.
- Net profit saw a remarkable increase of 23%, demonstrating the effectiveness of Novonesis's business model.
Revised Full-Year Outlook
The company has honed its outlook for the year, now predicting organic sales growth of 6-8%, an improvement from the previous guidance. Without the impact of exiting certain markets, the growth forecast stands at 7-9%. Furthermore, Novonesis aims to maintain its EBITDA margin between 37-38%, despite facing significant challenges posed by currency fluctuations.
Share Buyback and Investor Confidence
To bolster investor confidence, Novonesis successfully completed a EUR 100 million share buyback program. This move reflects the company’s commitment to returning value to shareholders while solidifying its financial standing as it continues to invest in growth opportunities.
Long-Term Financial Goals and Strategy
Looking ahead, Novonesis has outlined its long-term financial targets towards 2030, focusing on strategies that enhance the company’s unique offerings in biosolutions. The proactive strategic planning is expected to significantly strengthen Novonesis's market position and expand its footprint in the biosolutions industry.
Upcoming Conference Call
The company is set to discuss its 2030 strategy in detail during an upcoming conference call where they will share insights about their long-term plans. This provides an essential opportunity for investors and stakeholders to gain a deeper understanding of Novonesis's vision.
Contact Information
For further inquiries, shareholders and investors are encouraged to reach out to the dedicated Investor Relations team at Novonesis:
- Tobias Bjorklund: +45 3077 8682, tobb@novonesis.com
- Anders Enevoldsen: +45 5350 1453, adev@novonesis.com
- Katrine Spedtsberg Poulsen: kats@novonesis.com
Media Relations:
- Jens Gamborg: +45 3077 7182, jgam@novonesis.com
Frequently Asked Questions
What were Novonesis's organic sales growth figures for H1?
Novonesis reported a strong organic sales growth of 9% in H1.
What is the updated full-year sales growth outlook for Novonesis?
The company has narrowed its sales growth outlook to 6-8% for the year.
How did Novonesis perform in emerging markets?
Emerging markets achieved an impressive organic sales growth rate of 12%.
What adjustments were made to the share buyback program?
Novonesis successfully completed a EUR 100 million share buyback program.
What are Novonesis's financial goals towards 2030?
The company has set ambitious long-term financial goals aimed at expanding its leadership in biosolutions.
